Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).

× No keyword cloud information.

10 in total

Review 1. New drugs under clinical evaluation in the United States.

Authors: S K Carter
Journal: Cancer Chemother Pharmacol Date: 1978 Impact factor: 3.333

2. Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells.

Authors: I Pályi; J Bence; K Szikla; L Hullán
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

Review 3. New cancer chemotherapy drugs in Europe.

Authors: G Mathé; L M van Putten
Journal: Cancer Chemother Pharmacol Date: 1978 Impact factor: 3.333

Review 4. Updates in IDH-Wildtype Glioblastoma.

Authors: Mary Jane Lim-Fat; James R Perry; Jawad M Melhem; Jay Detsky
Journal: Neurotherapeutics Date: 2022-05-31 Impact factor: 6.088

5. Effect of a single high dose and repeated small doses of dianhydrogalactitol (DAG; NSC-132313) on rat intestinal mucosa.

Authors: J Kralovánszky; N Prajda; S Kerpel-Fronius; F Gál; Z Szentirmay
Journal: Cancer Chemother Pharmacol Date: 1983 Impact factor: 3.333

6. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.

Authors: E Institóris; K Szikla; L Otvös; F Gál
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

7. Alkylation by 1,2:5,6-dianhydrogalactitol of deoxyribonucleic acid and guanosine.

Authors: E Institóris; J Tamás
Journal: Biochem J Date: 1980-03-01 Impact factor: 3.857

8. The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol.

Authors: S Kerpel-Fronius; V Erdélyi-Tóth; S Somfai-Relle; J Csetényi; P Kovács; G Ujj; B Kanyár
Journal: Cancer Chemother Pharmacol Date: 1988 Impact factor: 3.333

9. Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma.

Authors: Miguel Jiménez-Alcázar; Álvaro Curiel-García; Paula Nogales; Javier Perales-Patón; Alberto J Schuhmacher; Marcos Galán-Ganga; Lucía Zhu; Scott W Lowe; Fátima Al-Shahrour; Massimo Squatrito
Journal: Mol Cancer Ther Date: 2021-04-12 Impact factor: 6.009

10. Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination.

Authors: Beibei Zhai; Anne Steinø; Jeffrey Bacha; Dennis Brown; Mads Daugaard
Journal: Cell Death Dis Date: 2018-10-03 Impact factor: 8.469

10 in total